ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: L01 • ACR Convergence 2024

    Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases

    Matthew Martin1, Erik Wilker1, Diana Gikunju1, Usha Narayanan1, Unnati Pandya1, Vijetha Prakash1, Ashley Edwards1, Sameer Kawatkar1, Tenghui Chen1, Ragunath Chandran1, Sai Sunder1, Sumathi Biradar1, Joerg Distler2, Alexandra Joseph1, Stephanos Ioannidis1 and Bhavatarini Vangamudi1, 1Exo Therapeutics, Cambridge, MA, 2Exo Therapeutics, Düsseldorf, Germany

    Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L19 • ACR Convergence 2024

    Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

    Alexei Grom1, Uwe Ullman2, Adnan Mahmood3, Josefin Blomkvist3, Brian Jamieson4 and Fabrizio De Benedetti5, 1Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 2Sobi, Basel, Switzerland, 3Sobi, Stockholm, Sweden, 4Sobi, Inc., Morrisville, NC, 5Bambino Gesu Children's Hospital, Rome, Italy

    Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
  • Abstract Number: 0010 • ACR Convergence 2024

    Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells

    Holly Wobma1, Francesca Alvarez-Calderon2, Jiayi Dong2, Alexandre Albanese2, Kayleigh Omdahl2, Rene Bermea3, Gillian Selig4, Marlana Winschel2, Elisa Rojas Palato2, Katherine Michaelis1, Xianliang Rui2, Bruce Blazar5, Susan Prockop2, Victor Tkachev3, Ulrike Gerdemann2 and Leslie Kean2, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, 3Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 4Harvard College, Boston, MA, 5Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN

    Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
  • Abstract Number: 0106 • ACR Convergence 2024

    IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS

    Christina Donath1, Sara Kahlown1, Ryan Soares2, Kamal Gautam2, Mariam Saleh3, Banki Katalin4 and Andras Perl5, 1SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, 2SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, 3SUNY Upstate University Hospital, Syracuse, NY, 4SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, 5SUNY, Syracuse, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
  • Abstract Number: 0257 • ACR Convergence 2024

    High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action

    Jaspreet Bhatti1, Kyu-In Lee1, Arushika Yedla1, Julia Ash1, James Miceli1, Kirk Sperber1 and Amy Wasserman2, 1Westchester Medical Center, Valhalla, NY, 2Westchester Medical Center, Valhalla

    Background/Purpose: Strongyloides Stercoralis is a human intestinal nematode widely found in tropical and subtropical regions that frequently causes chronic and asymptomatic infection (Table 1). Immunosuppression in a host…
  • Abstract Number: 0331 • ACR Convergence 2024

    Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

    Sangmee Bae1, Gianluca sambataro2, iazsmin Ventura3, Francisca Bozan4, Eduardo Dourado5, Sara Faghihi-Kashani6, Aravinthan Loganathan7, Daphne Rivero Gallegos8, Akira Yoshida9, Giovanni Zanframundo10, Francesco Bonella11, Tamera J Corte12, Tracy J Doyle13, david fiorentino14, Miguel Angel Gonzalez-Gay15, marie Hudson16, Masataka Kuwana17, Andrew Mammen18, Neil McHugh19, Frederick Miller20, Carlomaurizio Montecucco21, Antonella Notarnicola22, Chester Oddis23, Jorge Rojas-Serrano24, Jens Schmidt25, Carlo A. Scire26, Albert Gil-Vila27, Victoria Werth28, Lorenzo Cavagna29 and Rohit Aggarwal30, 1UCLA, Los Angeles, CA, 2University of Catania, Catania, Italy, 3Section of Rheumatology, University of Chicago, Chicago, IL, 4Hospital Clinico Universidad de Chile, Santiago, Chile, 5Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, 6Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8INER, Ciudad de México, Mexico State, Mexico, 9Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 10Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, 11Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 12Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, 13Brigham and Women's Hospital, West Roxbury, MA, 14Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, 15University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 16McGill University, Montreal, QC, Canada, 17Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 18NIH, Bethesda, MD, 19University of Bath, Bath, United Kingdom, 20NIH, NIEHS, Chapel Hill, NC, 21IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 22Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 23Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 24National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, 25University Medical Center Goettingen, Göttingen, Germany, 26University of Milano Bicocca, Milan, Italy, 27Universitat Autònoma of Barcelona, Barcelona, Spain, 28University of Pennsylvania, Wynnewood, PA, 29University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, 30Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…
  • Abstract Number: 0536 • ACR Convergence 2024

    A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease

    Claire Mukashyaka1, Xiaodong Wang1, Sujata Arora1, Mason Yamashita1, Allen Poma1 and Tanya Fischer2, 1Zenas BioPharma, Waltham, MA, 2Zenas BioPharma, Waltham, CA

    Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
  • Abstract Number: 0775 • ACR Convergence 2024

    A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings

    John Stone1, Emma Culver2, Arezou Khosroshahi3, Wen Zhang4, Emanuel Della Torre5, Kazuichi Okazaki6, Yoshiya Tanaka7, Matthias Löhr8, Nicolas Schleinitz9, Lingli Dong10, Hisanori Umehara11, Marco Lanzillotta12, Zachary Wallace13, Mikael Ebbo14, George Webster15, Ferran Martinez Valle16, Manu Nayar17, Vinciane Rebours18, Cory Perugino19, Xinxin Dong20, Yanping Wu20, Nishi Rampal20 and Daniel Cimbora20, 1Massachusetts General Hospital , Harvard Medical School, Concord, MA, 2John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 3Emory University, Atlanta, GA, 4Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 5Ospedale San Raffaele, Milan, Italy, 6University of Occupational and Environmental Health, Osaka, Japan, 7Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 8Karolinska Institutet, Stockholm, Sweden, 9Aix Marseille university, AP-HM, Marseille, France, 10Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), 11Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, 12IRCCS Ospedale San Raffaele, Milano, Italy, 13Massachusetts General Hospital, Newton, MA, 14Aix-Marseille Université, Marseille, France, 15University College Hospital London, London, United Kingdom, 16Vall d’Hebron Hospital, Barcelona, Spain, 17Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 18Beaujon Hospital, Université Paris-Cité, France, 19Massachusetts General Hospital, Boston, MA, 20Amgen Inc., Thousand Oaks, CA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
  • Abstract Number: 0860 • ACR Convergence 2024

    Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases

    Xiangyi Shen1, Xu Jiang2, Yangzhige He2 and Huaxia Yang3, 1Tsinghua University, Beijing, China, 2National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Background/Purpose: Autoimmune diseases (AIDs) increase the risk of cancer and impose a substantial socioeconomic burden worldwide. However, the biological characteristics of cancer as a comorbidity…
  • Abstract Number: 0940 • ACR Convergence 2024

    Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop

    Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
  • Abstract Number: 1107 • ACR Convergence 2024

    Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective

    Carine Moezinia1, Jan Nouza2, Beatrice Hornstein-Lasry2, Luai Kawar2, Asim Khan2 and Jessica Manson2, 1University College London Hospital, London, England, United Kingdom, 2University College London Hospital, London, United Kingdom

    Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
  • Abstract Number: 1304 • ACR Convergence 2024

    Assessing Knowledge and Aptitude in Antinuclear Antibody Testing Among Internal Medicine Residents

    Dania Kaur1, Fizza Zulfiqar2, Akanksha Sharma3, Muhammad Bilal4, Rida Fatima4 and Abhinav Vyas5, 1North Alabama Medical Center, Muscle Shoals, AL, 2Trinity Health Oakland/Wayne State University, Pontiac, MI, 3UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, 4Bassett Medical Center, Cooperstown, NY, 5Vanderbilt University Medical Center, Nahville, TN

    Background/Purpose: Testing for antinuclear antibodies (ANA) is essential for diagnosing autoimmune and rheumatologic diseases. The testing has become increasingly popular in primary and specialized clinics,…
  • 1
  • 2
  • 3
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology